Nat Med breakthrough: discovery of an effective and long-term HIV inhibitor
-
Last Update: 2019-09-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
September 17, 2019 / bioun / -- people living with HIV (PLWH) are worried about the life-long burden and stigma of daily medication As they may experience drug fatigue, it may lead to poor treatment compliance and drug-resistant virus variation, thus limiting future treatment options As a result, there is a strong interest in long-acting antiretroviral drugs (ARV) because of their low frequency of use For this reason, Stephen R Yant and his colleagues, together with collaborators from the University of Utah School of medicine and the University of Massachusetts School of medicine, reported a new small molecule HIV capsid inhibitor, gs-ca1, which has special effects on HIV-2 and all major HIV-1 types, including virus variants that are resistant to antiretroviral drugs currently in clinical use Photo source: Nature Medicine researchers have studied the mechanism of action of gs-ca1, which shows that gs-ca1 can directly bind to HIV-1 capsid, interfering with capsid mediated nuclear transfer of viral DNA, production of HIV particles and orderly capsid assembly The researchers found that the inappropriately selected variant capsid resistant to gs-ca1 in vitro was still completely sensitive to other types of ARVs Gs-ca1 has high metabolic stability and low solubility, which can make the drug release continuously in mice Therefore, it has a better antiviral effect only by subcutaneous administration In a humanized mouse model infected with HIV-1, the researchers found that gs-ca1, as a long-term single drug injection therapy, showed a high antiviral effect, and its effect was better than that of long-term ribavirin All in all, these results indicate the potential of strong capsid inhibitors as new long-acting drugs for HIV-1 infection Reference: Stephen R Yant et al A high potent long-acting small-molecular HIV-1 capsid inhibitor with efficient in a humanized mouse model Nature medicinevolume 25, pages 1377-1384 (2019) DOI https://doi.org/10.1038/s41591-019-0560-x
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.